Meeting
2013 ASCO Annual Meeting
Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody.
Authors
Katja Schindler
Medical University of Vienna, Vienna, Austria
Katja Schindler , Kaan Harmankaya , Michael Andrew Postow , Sophie Frantal , Danielle Bello , Charlotte Eielson Ariyan , Olivier Alain Michielin , Christoph Hoeller , Hubert Pehamberger , Jedd D. Wolchok
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9024)
DOI
10.1200/jco.2013.31.15_suppl.9024
Abstract #
9024
Poster Bd #
12
Abstract Disclosures
Similar Posters
First Author: Typhanie Carré
Poster
2021 ASCO Annual Meeting
Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.
First Author: Nienke A De Glas
Poster
2019 ASCO Annual Meeting
Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma.
First Author: Kaysia Ludford
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Autoimmune toxicities with anti-PD-1 treatment of metastatic melanoma in predominantly older patients: A single institutional experience.
First Author: Harsh V Parmar